FDA panel votes that a controversial premature birth medication should be withdrawn; FDA authorizes booster shot for Novavax’s Covid-19 vaccine

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: FDA panel votes that a controversial premature birth medication should be withdrawn By Ed Silverman Adobe The highly unusual hearing was closely watched because it was seen as a test of the ability of the FDA to exercise its authority. Read More Opinion: What the Makena vote means about accelerated approval, trust, and the FDA By Mikkael A. Sekeres Sarah Silbiger/Getty Images The vote to pull Makena off the market is the right decision. But the FDA needs to better communicate why some drugs deserve this. Read More Sponsored Insight by Alexion Why don't we have more treatments for rare diseases? Although there are financial incentives for the research and development of rare disease treatments, their path to approval is often rocky. The patient population for any single rare disease is so small that it's time-consuming, costly, and often impossible to recruit people for the clinical trials needed to bring a drug to market. Learn more here. FDA authorizes booster shot for Novavax's Covid-19 vaccine By Helen Branswell JUSTIN TALLIS/AFP via Getty Images Unlike the latest boosters from Pfizer-BioNTech and Moderna, the Novavax booster only targets the original strain of SARS-CoV-2. Read More Listen: What makes food 'healthy' and why we don't prioritize nutrition By Patrick Skerrett In this week's First Opinion Podcast, nutrition policy expert @marionnestle talks about the FDA's new food labels, and the problem with "food products." Read More Wednesday, October 19, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser